Renaissance Capital logo

Bio Blast Pharma Priced, Nasdaq: ORPN

Biotech developing treatments for rare and ultra-rare genetic diseases.

Industry: Health Care

First Day Return: -23.6%

Biotech developing treatments for rare and ultra-rare genetic diseases.

Bio Blast Pharma (ORPN) Performance

Created with Highcharts 10.3.2Chart context menuORPN vs. IPO Index (IPOUSA)20152016201720182019202020212022202320242025-100%0%+ 100%+ 200%+ 300%View 5 days5dView 1 month1mView 3 months3mView year to dateYTDView 1 year1yView allAllRenaissance IPO IndexOur ETF tracks the IPO Index